David R. Bauer

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock…

Davis Polk is advising First Data Corporation on the formation of a joint venture with FLEETCOR Technologies Inc. The new joint venture combines the gift card businesses of both companies…

Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…

Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…

Davis Polk advised Advanced Accelerator Applications S.A. on its approximately $150 million SEC-registered follow-on offering of American Depositary Shares representing its ordinary shares…

Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…

Davis Polk is advising Chemtura Corporation in connection with its approximately $2.5 billion acquisition by LANXESS AG. The transaction, which is expected to close around mid-2017, is…

Davis Polk advised Shire plc on the $12.1 billion SEC-registered debt offering by its wholly owned subsidiary, Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), consisting of $3.3…